How to Buy Cidara Therapeutics Stock
Cidara Therapeutics Inc
Cidara Therapeutics, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.
Cidara Therapeutics stock last closed at $44.95, up 113.84% from the previous day, and has increased 298.14% in one year. It has overperformed other stocks in the Biotechnology industry by 3.7 percentage points. Cidara Therapeutics stock is currently +343.29% from its 52-week low of $10.14, and -0.97% from its 52-week high of $45.39.
At the moment, there are 12.97M CDTX shares outstanding. The market capitalization of CDTX is $582.99M. In the past 24 hours, 6.59M CDTX shares were traded.
How to Buy Cidara Therapeutics Stock
Not sure how to invest in Cidara Therapeutics stock? Here's how.
- Decide where to buy Cidara Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Cidara Therapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your method of payment and add your information.
- Analyze Cidara Therapeutics stock: The Cidara Therapeutics ticker symbol is CDTX. Is Cidara Therapeutics stock a good investment? Should you buy shares of CDTX? How do CDTX's underlying business fundamentals look? Do top analysts think Cidara Therapeutics is a good buy? Why has CDTX's stock price moved recently? (Hint: Our stock research tools can help you evaluate if CDTX is a good stock to buy).
- Execute your CDTX buy order: Decide if you will purchase CDTX shares at the current market price or use a limit order to buy CDTX shares at a given price.
- Watch your investment in CDTX: Create a watchlist to important updates regarding your investment in Cidara Therapeutics stock.
Step 1: Decide where to buy Cidara Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy CDTX stock.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Technology to Utilities, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the best brokerage, the next step is to fill out some personal info so you can invest in CDTX stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to start a new trading account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have created your account on app for investing, you can securely and quickly fund your account:
Check out this video walkthrough if you need help depositing funds into your brokerage account.
Step 4: Analyze Cidara Therapeutics stock
After you have chosen the best place to buy Cidara Therapeutics stock, it's absolutely critical to research their stock prior to investing, so you actually wrap your head around the risk as well as the opportunity.
Cidara Therapeutics shares data
CDTX Due Diligence Score
WallStreetZen was designed to help part-time investors perform more accurate fundamental analysis in less time.
You can view all of the due diligence checks on CDTX's stock page.
How is CDTX stock valued?
You can use many financial metrics, analyses, models, and charts to gauge CDTX's intrinsic value.
Using relative valuations measures:
- CDTX could be undervalued based on its P/B ratio of 4.11x, relative to Biotechnology industry P/B ratio of 4.42x
You can access more valuation research on CDTX's stock here.
CDTX Financial Health
Signs that CDTX is financially healthy:
- There are more short-term assets than long-term liabilities on the CDTX balance sheet.
- CDTX has a low debt to equity ratio of 0.35.
- There are more short-term assets than short-term liabilities on the CDTX balance sheet.
- Total CDTX debt is lower than 5 years ago, relative to shareholder equity.
Signs that CDTX is not financially healthy:
- CDTX profit margin has gone down from -201.1% to -60,589.7% in the past year.
- CDTX has cash burn of 191760000. It does not have sufficient cash and short-term investments to cover this.
- CDTX has $174.49M in cash and short term investments. This is not sufficient to cover its annual cash burn of $191.76M.
Is it a good time to buy Cidara Therapeutics stock, according to Wall Street analysts?
Out of 7 Equities analysts who give recommendations on CDTX, the consensus analyst rating on Cidara Therapeutics is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Latest CDTX Analyst Recommendations
Seamus Fernandez, a top 14% analyst from Guggenheim maintains CDTX with a strong buy rating and raises their CDTX price target from $35.00 to $50.00, on May 16, 2025.
Guggenheim's Seamus Fernandez raised their price target on Cidara Therapeutics (NASDAQ: CDTX) by 42.9% from $35 to $50 on 2025/05/16. The analyst maintained their Strong Buy rating on the stock.
Cidara Therapeutics reported its Q1 2025 earnings on 2025/05/08.
Previewing the company's Analyst Day on 2025/05/22 and top-line NAVIGATE Phase 2b data in late 2025/06, Fernandez adjusted their model on "increased enthusiasm" for CD388's efficacy and possible pricing power.
The analyst said they are "increasingly bullish on CD388's multi-blockbuster potential."
Earnings Report
For Q1 2025, Cidara Therapeutics reported:
- Loss per share of $1.66, up from Q1 2024's $(2.28).
- Revenue of $0.00, down from Q1 2024's $973,000.
President & CEO Jeffrey Stein, Ph.D., commented: “Coinciding with the end of the 2024-2025 flu season in the Northern Hemisphere, we have established April 30, 2025 as the data cutoff for the primary efficacy analysis of the 5,041 subjects dosed in the Phase 2b NAVIGATE clinical trial.
"We are expecting top-line results in late June of this year.
"The severity of the 2024-2025 flu season has provided an opportunity to discuss changes to the study’s statistical analysis plan with the U.S. FDA to evaluate the potential statistical significance of CD388 versus placebo.
“We believe CD388 is highly differentiated from vaccines and monoclonal antibodies, and we believe these differences can significantly improve upon the protective efficacy against influenza in healthy, high-risk, and immunocompromised patients with a single dose per flu season.”
Ed Arce, a top 3% analyst from HC Wainwright & Co. maintains CDTX with a buy rating and raises their CDTX price target from $24.00 to $35.00, on Mar 10, 2025.
You can dig deeper into what analysts are saying on the Cidara Therapeutics stock forecast page.
CDTX Trading Indicators
CDTX Performance Metrics
Last year, CDTX revenue was $302.00k. During the last 5 year, CDTX's revenue has gone up by -58.12% per year. This was slower than the Biotechnology industry average of 42.87%.
Dig into CDTX's earnings and revenue performance here.
Who is buying/selling CDTX?
In the last year, insiders at CDTX have bought more shares than they have sold.
Chrysa Mineo, Director of CDTX, was the latest CDTX insider to buy. They bought $24,614.10 worth of CDTX shares on Jun 3, 2025.
Research more about who owns CDTX shares here.
Does CDTX provide a stable income stream?
No, Cidara Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about CDTX
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your CDTX buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a specific dollar amount, place a limit order.
Click the Open button and eToro will execute the order.
If you need additional help investing in stocks on eToro, watch the helpful video below:
Step 6: Watch your investment in CDTX
Now that you own some CDTX shares, you'll want to stay up-to-date on your stock purchase.
Start a watchlist to get notified of important updates regarding your CDTX stock.
CDTX Feed
How to Buy Stock in Cidara Therapeutics
To reiterate, here are the 6 steps to buy Cidara Therapeutics stock:
- Decide where to buy Cidara Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Analyze Cidara Therapeutics stock
- Execute your CDTX buy order
- Watch your investment in CDTX
If you need a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep tabs on your new investment in Cidara Therapeutics, add CDTX to your watchlist by clicking the button below.
Other Content You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.